Clinical trials: Cancer of Head and Neck
HNSCC, SCC - Squamous Cell Carcinoma
Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)
The goal of this clinical trial is to learn whether intratumoral (injected directly into the tumor) fluorescently labeled nivolumab (nivo800) is safe for adults with head and neck squamous cell carcinoma (HNSCC) who are scheduled…
- Conditions
- HNSCC, SCC - Squamous Cell Carcinoma, Oral Cancer
- Trial name
- NCT07741565
- Testing
- Nivolumab-IRDye800
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cancer
Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
The purpose of this study is to determine if the addition of a unique targeted agent called Cetuximab (also known as "C225" and "Erbitux") can increase the effectiveness of standard treatment with chemotherapy and radiation.
- Trial name
- NCT00226239
- Testing
- Docetaxel, Cisplatin, Cetuximab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pittsburgh
Esophageal Squamous Cell Carcinoma, Stage III
Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)
The purpose of this study is to observe and evaluate the efficacy and safety of pembrolizumab plus paclitaxel, cisplatin followed by Da Vinci robot radical surgery for locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT04389177
- Testing
- Pembrolizumab Injection [Keytruda]
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Adult Solid Tumor
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
The purpose of this study is to test the CANscript™ sensitivity assay, which is a new and different assay developed to test the sensitivity of different cancer types to physician selected therapies (both drugs and/or drug…
- Trial name
- ANCERS-2 (NCT03253575)
- Testing
- CANscript
- Where
- 30 sites in United States
- Volunteers
- 800 people
- Sponsor
- Mitra RxDx, Inc.
Head and Neck Squamous Cell Cancer
Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
This is a Phase I/IIa, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccine delivered by electroporation (EP) to participants with human papilloma virus (HPV) associated head and neck…
- Trial name
- NCT02163057
- Testing
- INO-3112, CELLECTRA™-5P
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Inovio Pharmaceuticals
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage III
- Trial name
- NCT03993353
- Testing
- Pembrolizumab, Tadalafil
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Diego
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
The standard of care for head and neck and lung cancer includes chemotherapy, radiation and surgery. For patients with cancer of head and neck or lung that recurs after surgery and/or radiation, or has spread to other parts of…
- Trial name
- NCT00901537
- Testing
- Azacitidine and Cisplatin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Loma Linda University
Lung Cancer, Esophageal Cancer
Assessment of Patient Frailty Prior to Thoracic Surgery
Determine the feasibility of assessment of measures of frailty and determine if these measures provide a clinically important contribution of risk assessment in a population of patients undergoing major thoracic surgery for lung…
- Trial name
- NCT02803281
- Testing
- Frailty Assessment
- Where
- 3 sites in Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Incurable Metastatic Colorectal Carcinoma, Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 1 and 2 Study of PX-866 and Cetuximab
The purpose of this Phase 1/2 open-label study is to determine the safety and efficacy of a cetuximab and PX-866 combination treatment.
- Trial name
- NCT01252628
- Testing
- PX-866 (SCCHN), Cetuximab (SCCHN), PX-866 (CRC)
- Where
- 40 sites in United States, Canada
- Volunteers
- 178 people
- Sponsor
- Cascadian Therapeutics Inc.
Advanced Solid Tumor, Lymphoma
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study.
- Conditions
- Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT04106167
- Testing
- Allogeneic natural killer (NK) cell
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fate Therapeutics
Esophageal Neoplasm, Esophageal Cancer TNM Staging Primary Tumor (T) T2
Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma;
The purpose of this study is to determine the efficacy of preventive intensity modulated radiation therapy after surgery in stage T2-3N0M0 disease of thoracic esophageal squamous cell carcinoma(UICC 7th edition) and to identify…
- Conditions
- Esophageal Neoplasm, Esophageal Cancer TNM Staging Primary Tumor (T) T2, Esophageal Cancer TNM Staging Primary Tumor (T) T3, Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0
- Trial name
- IMRT (NCT01745107)
- Testing
- Prophylactic postoperative radiation therapy
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Chinese Academy of Medical Sciences
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
This study is a single center, non controlled, prospective phase II clinical trial to evaluate the efficacy and safety of Sacituzumab Tirumotecan and Toripalimab in the first-line treatment of recurrent/metastatic head and neck…
- Trial name
- NCT07088211
- Testing
- Sacituzumab Tirumotecan and Toripalimab
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Epiphora
Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel
Objective: To evaluate the safety and efficacy of topical cyclosporine eye drops (Restasis®) for the treatment of epiphora caused by canalicular stenosis secondary to Docetaxel (Taxotere®) treatment for various cancers.
- Trial name
- NCT00824811
- Testing
- Cyclosporine Eye Drops (Restasis), Lubricant Eye Drops (Refresh Endura™), Fluorometholone Eye Drops (FML Forte®)
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Cancer, Chemoradiation
S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer
This was a randomised, multicenter, phase 3 trial. Patients who were age of 70 years or older with histologically confirmed esophageal cancer were randomly assigned to S-1 concurrent with radiotherapy or radiotherapy alone.The…
- Trial name
- NCT02813967
- Testing
- Radiotherapy 54 Gy, Radiotherapy 60 Gy, S-1
- Where
- China
- Volunteers
- 298 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Neoplasms
The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT
The purpose of this study is to determine whether Intensity-modulated radiation therapy (IMRT) combined inductive and concurrent chemotherapy with more intensive regimen (cisplatin and paclitaxel) is feasible and effective than…
- Trial name
- NCT01797900
- Testing
- Cisplatin, Paclitaxel, IMRT
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Chinese Academy of Medical Sciences
Head and Neck Squamous Cell Carcinoma
A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
The primary objective of this clinical study is to compare the pharmacokinetic parameters of drugs RPH-002 and Erbitux® after a single intravenous administration, as well as to evaluate the safety of drug RPH-002 in comparison…
- Trial name
- NCT07435311
- Testing
- RPH-002, Erbitux®, cisplatin
- Where
- 18 sites in Russia
- Volunteers
- 118 people
- Sponsor
- R-Pharm
Anastomotic Leak, Esophageal Cancer
Assessment of Graft Perfusion and Oxygenation for Improved Outcome in Esophageal Cancer Surgery
After the esophagectomy, the stomach is most commonly used to restore continuity of the upper gastro-intestinal tract. The esophagogastric anastomosis is prone to serious complications such as anastomotic leakage (AL) The…
- Trial name
- EDOBS (NCT03587532)
- Testing
- Indocyanine green angiography, Hemodynamic evaluation, Biological and pathological markers of ischemia
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- University Hospital, Ghent
Esophageal Squamous Cell Carcinoma
AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma
The purpose of this study is to assess the safety and efficacy of AK104 plus concurrent chemoradiation therapy in unresectable locally advanced esophageal squamous cell carcinoma
- Trial name
- NCT05594914
- Testing
- AK104
- Volunteers
- 47 people
- Sponsor
- The First Affiliated Hospital of University of South China
Oral Cancer
Expression of VEGF-C and VEGF-CR in Oral Cancers and Premalignant Lesions
The role of vascular endothelial growth factor-C (VEGF-C) and its receptors induced lymphangiogenesis and host inflammatory responses on the carcinogenesis of oral cancers and premalignant lesions
- Trial name
- NCT00173316
- Where
- Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Melanoma, Squamous Cell Carcinoma of Head and Neck
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment.
- Trial name
- NCT05280314
- Testing
- IO102-IO103, Pembrolizumab KEYTRUDA®
- Where
- 15 sites in United States, Australia and 4 more
- Volunteers
- 60 people
- Sponsor
- IO Biotech